On June 20, we welcomed Oliver Schönborn-Kellenberger, co-founder and CEO of Cogitars for the M2M interview.
Cogitars provides statistical support for Biotech- and Pharma Companies including Bayesian trials in phase 1, ranging from technical implementation to protocol writing and negotation with regulators.
Cogitars, from Latin “The Art of Thinking”, was founded 10 years ago and accelerated by the HAE Accelerator program from BioRN. The company grew in the last years dynamically, adapting to trends and keeping offering essential support to pharma, medtech and diagnostic companies in the region.
Discover how they can support you in the full interview on-demand